홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Trimebutine

HCID 5573
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
39133-31-8
표준 SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
분자식
C22H29NO5
평균 분자량
387.5 g/mol
단동위원소 질량
387.20457303

개요

3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester is a trihydroxybenzoic acid.

이름 및 식별자

우선 이름
Trimebutine
IUPAC
[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
영어명
Trimebutine
분자식
C22H29NO5
분자량
387.47

이름 및 동의어

trimebutine39133-31-8TrimebutinumTrimebutina2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoateTransacalmModulon2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoatQZ1OJ92E5RMaleate, TrimebutineMaleate Salt, TrimebutineSalt, Trimebutine Maleate
이름 더 보기
3,4,5-TRIMETHOXYBENZOIC ACID 2-[DIMETHYLAMINO]-2-PHENYLBUTYL ESTERMebutinTRIMEBUTINAPI Trimebutinetrimebutine free baseTrimebutine USP/EP/BPTrimebutine hydrochlorideTRIMEBUTINE 0.787% GRANULESCholesterol hemisuccinate Tris salt
DTXSID4023707(+-)-TrimebutineRefChem:389346DTXCID503707A03AA05TM906254-309-2Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

데이터베이스 식별자

CAS
39133-31-8、58997-89-0、58997-90-3
PubChem CID
5573
DTXSID
DTXSID4023707
ChEMBL
CHEMBL190044
ChEBI
CHEBI:94458
UNII
9RKX7S7WFY、QZ1OJ92E5R、U4UUZ24TRB
EC Number
254-309-2、261-548-6
Nikkaji
J15.812G、J304.096H、J304.097F

물성

구조 계산 물성

XLogP
4
극성 표면적
57.2 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
6
회전 가능 결합 수
10
무거운 원자 수
28
형식 전하
0
복잡도
466

실험 및 물리화학적 성질

DrugsPharmaceutical
SolubilityInsoluble
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point78-82
Collision Cross Section193.19 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
78 · 78-80°C
끓는 점
513.42 °C · 513.42°C (rough estimate)
밀도
1.1998 · 1.1998 (rough estimate)
굴절률
1.5614 · 1.5614 (estimate)
저장 조건
2 · 2-8°C
용해도
클로로포름 (약간 용해됨), 에틸아세테이트 (약간 용해됨), 메탄올(살짝살짝용해됨)
물리적 상태
Solid
산도 계수 (pKa)
7.29 · 7.29±0.50(Predicted)
색상
흰색에서 황백색까지
수용성
10 g/L · 10g/L

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 61.5% (8 of 13) of all reports.

Warning

H302 (23.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 13 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 2건

Chemical: Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester

REACH registered substance: Trimebutine (EC: 254-309-2)

Hazard Classes and CategoriesAcute Tox. 4 (23.1%)

독성 정보

Drug Induced Liver Injury · 4건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimebutine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

안전 데이터

wgk
3
HS 번호
2922.19.0900
기존화학 물질
KE-34359
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingProtein binding is minimal with 5% in vivo and in vitro to serum albumin.
Pharmacodynamics · 1건

Trimebutine is a spasmolytic agent that acts directly on smooth muscle to modulate gastric motility. It shows a "dual function" that stimulates or inhibits spontaneous contractions depending on the concentration and prior contractile activity in the preparation. Targeting ion conductance that regulates GI motility, trimebutine inhibits the inward calcium currents and calcium-dependent potassium currents in a concentration-dependent manner. At lower concentrations (1-10uM), trimebutine depolarizes the resting membrane potential without affecting the amplitude of contractions, which is thought to be mediated by inhibition of outward potassium currents. It is also shown to activate T-type Ca2+ channel and increase gastric emptying, intestinal and colonic contractility. At higher concentrations (100-300uM), reduced amplitude of spontaneous contractions and action potentials is thought to be mediated by inhibition of L-type Ca2+ channels and inward calcium current. Trimebutine mediates a local anesthetic action by acting as a weak agonist at mu opioid receptors.

Mechanism of Action · 1건

At high concentrations, trimebutine is shown to inhibit the extracellular Ca2+ influx in the smooth muscle cells through voltage dependent L-type Ca2+ channels and further Ca2+ release from intracellular Ca2+ stores. Trimebutine is suggested to bind to the inactivated state of the calcium channel with high affinity. Reduced calcium influx attenuates membrane depolarization and decrease colon peristalsis. It also inhibits outward K+ currents in response to membrane depolarization of the GI smooth muscle cells at resting conditions through inhibition of delayed rectifier K+ channels and Ca2+ dependent K+ channels, which results in induced muscle contractions. Trimebutine binds to mu opioid receptors with more selectivity compared to delta or kappa opioid receptors but with lower affinity than their natural ligands. Its metabolites (N-monodesmethyl-trimebutine or nor-trimebutine), are also shown to bind to opoid receptors on brain membranes and myenteric synaptosomes.

관련 반응

2건
반응 기록 만들기
HRID 1445952 반응식
HRID 1445952반응물로
HRID 1879077 반응식
HRID 1879077반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
Merck
14 · 14,9699
주요 응용
법의학 및 독성학의약품(소분자)수의사
InChI
1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
SMILES
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c2ccccc2
Biological Half-LifeThe elimination half life is approximately 1 hour following a single oral dose of 2mg/kg, and 2.77 hours following a single oral dose 200 mg.
Metabolism/Metabolites · 1건

Trimebutine undergoes extensive hepatic first-pass metabolism. Nortrimebutine, or N-monodesmethyltrimebutine, is the main metabolite that retains pharmacological activity on the colon. This metabolite can undergo second N-demethylation to form N-didesmethyltrimebutine. Other main urinary metabolites (2-amino, 2-methylamino or 2-dimethylamino-2-phenylbutan-1-ol) can be formed via hydrolysis of the ester bond of desmethylated metabolites or initial hydrolysis of the ester bond of trimebutine followed by sequential N-demethylation. Trimebutine is also prone to sulphate and/or glucuronic acid conjugation.

MeSH Pharmacological Classification · 2건

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.

Absorption, Distribution and Excretion · 3건

The free base form or salt form of trimebutine are rapidly absorbed after oral administration, with the peak plasma concentration reached after 1 hour of ingestion. The time to reach peak plasma concentration following a single oral dose of 200mg trimebutine is 0.80 hours.

Renal elimination is predominant while excretion into feces is also observed (5-12%). About 94% of an oral dose of trimebutine is eliminated by the kidneys in the form of various metabolites and less than 2.4% of total ingested drug is recovered as unchanged parent drug in the urine.

Trimebutine is most likely to be accumulated in the stomach and the intestinal walls in highest concentrations. The fetal transfer is reported to be low.

응용 분야

용도Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.

상·하류 제품 정보

상류 원료

2-Amino-2-phenylbutyric acid